777 related articles for article (PubMed ID: 25611208)
1. Empagliflozin, an Inhibitor of Sodium-Glucose Cotransporter 2 Exerts Anti-Inflammatory and Antifibrotic Effects on Experimental Diabetic Nephropathy Partly by Suppressing AGEs-Receptor Axis.
Ojima A; Matsui T; Nishino Y; Nakamura N; Yamagishi S
Horm Metab Res; 2015 Aug; 47(9):686-92. PubMed ID: 25611208
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of kidney proximal tubular glucose reabsorption does not prevent against diabetic nephropathy in type 1 diabetic eNOS knockout mice.
Gangadharan Komala M; Gross S; Mudaliar H; Huang C; Pegg K; Mather A; Shen S; Pollock CA; Panchapakesan U
PLoS One; 2014; 9(11):e108994. PubMed ID: 25369239
[TBL] [Abstract][Full Text] [Related]
3. Sodium-glucose cotransporter 2-mediated oxidative stress augments advanced glycation end products-induced tubular cell apoptosis.
Maeda S; Matsui T; Takeuchi M; Yamagishi S
Diabetes Metab Res Rev; 2013 Jul; 29(5):406-12. PubMed ID: 23508966
[TBL] [Abstract][Full Text] [Related]
4. The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity.
Oelze M; Kröller-Schön S; Welschof P; Jansen T; Hausding M; Mikhed Y; Stamm P; Mader M; Zinßius E; Agdauletova S; Gottschlich A; Steven S; Schulz E; Bottari SP; Mayoux E; Münzel T; Daiber A
PLoS One; 2014; 9(11):e112394. PubMed ID: 25402275
[TBL] [Abstract][Full Text] [Related]
5. Tofogliflozin, A Highly Selective Inhibitor of SGLT2 Blocks Proinflammatory and Proapoptotic Effects of Glucose Overload on Proximal Tubular Cells Partly by Suppressing Oxidative Stress Generation.
Ishibashi Y; Matsui T; Yamagishi S
Horm Metab Res; 2016 Mar; 48(3):191-5. PubMed ID: 26158396
[TBL] [Abstract][Full Text] [Related]
6. The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension.
Gembardt F; Bartaun C; Jarzebska N; Mayoux E; Todorov VT; Hohenstein B; Hugo C
Am J Physiol Renal Physiol; 2014 Aug; 307(3):F317-25. PubMed ID: 24944269
[TBL] [Abstract][Full Text] [Related]
7. Pigment epithelium-derived factor (PEDF) inhibits proximal tubular cell injury in early diabetic nephropathy by suppressing advanced glycation end products (AGEs)-receptor (RAGE) axis.
Maeda S; Matsui T; Takeuchi M; Yoshida Y; Yamakawa R; Fukami K; Yamagishi S
Pharmacol Res; 2011 Mar; 63(3):241-8. PubMed ID: 21115116
[TBL] [Abstract][Full Text] [Related]
8. Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats.
Tahara A; Kurosaki E; Yokono M; Yamajuku D; Kihara R; Hayashizaki Y; Takasu T; Imamura M; Li Q; Tomiyama H; Kobayashi Y; Noda A; Sasamata M; Shibasaki M
J Pharm Pharmacol; 2014 Jul; 66(7):975-87. PubMed ID: 24533859
[TBL] [Abstract][Full Text] [Related]
9. Glucagon-like peptide-1 receptor agonist inhibits asymmetric dimethylarginine generation in the kidney of streptozotocin-induced diabetic rats by blocking advanced glycation end product-induced protein arginine methyltranferase-1 expression.
Ojima A; Ishibashi Y; Matsui T; Maeda S; Nishino Y; Takeuchi M; Fukami K; Yamagishi S
Am J Pathol; 2013 Jan; 182(1):132-41. PubMed ID: 23159951
[TBL] [Abstract][Full Text] [Related]
10. Metformin inhibits advanced glycation end products (AGEs)-induced renal tubular cell injury by suppressing reactive oxygen species generation via reducing receptor for AGEs (RAGE) expression.
Ishibashi Y; Matsui T; Takeuchi M; Yamagishi S
Horm Metab Res; 2012 Nov; 44(12):891-5. PubMed ID: 22864903
[TBL] [Abstract][Full Text] [Related]
11. Effects of SGLT2 inhibition in human kidney proximal tubular cells--renoprotection in diabetic nephropathy?
Panchapakesan U; Pegg K; Gross S; Komala MG; Mudaliar H; Forbes J; Pollock C; Mather A
PLoS One; 2013; 8(2):e54442. PubMed ID: 23390498
[TBL] [Abstract][Full Text] [Related]
12. The anti-inflammation effect of Moutan Cortex on advanced glycation end products-induced rat mesangial cells dysfunction and High-glucose-fat diet and streptozotocin-induced diabetic nephropathy rats.
Zhang MH; Feng L; Zhu MM; Gu JF; Jiang J; Cheng XD; Ding SM; Wu C; Jia XB
J Ethnopharmacol; 2014; 151(1):591-600. PubMed ID: 24269777
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment.
Macha S; Mattheus M; Halabi A; Pinnetti S; Woerle HJ; Broedl UC
Diabetes Obes Metab; 2014 Mar; 16(3):215-22. PubMed ID: 23859488
[TBL] [Abstract][Full Text] [Related]
14. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice.
Vallon V; Gerasimova M; Rose MA; Masuda T; Satriano J; Mayoux E; Koepsell H; Thomson SC; Rieg T
Am J Physiol Renal Physiol; 2014 Jan; 306(2):F194-204. PubMed ID: 24226524
[TBL] [Abstract][Full Text] [Related]
15. Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice.
Gallo LA; Ward MS; Fotheringham AK; Zhuang A; Borg DJ; Flemming NB; Harvie BM; Kinneally TL; Yeh SM; McCarthy DA; Koepsell H; Vallon V; Pollock C; Panchapakesan U; Forbes JM
Sci Rep; 2016 May; 6():26428. PubMed ID: 27226136
[TBL] [Abstract][Full Text] [Related]
16. Disparate effects on renal and oxidative parameters following RAGE deletion, AGE accumulation inhibition, or dietary AGE control in experimental diabetic nephropathy.
Tan AL; Sourris KC; Harcourt BE; Thallas-Bonke V; Penfold S; Andrikopoulos S; Thomas MC; O'Brien RC; Bierhaus A; Cooper ME; Forbes JM; Coughlan MT
Am J Physiol Renal Physiol; 2010 Mar; 298(3):F763-70. PubMed ID: 20015941
[TBL] [Abstract][Full Text] [Related]
17. Beneficial effects of metformin and irbesartan on advanced glycation end products (AGEs)-RAGE-induced proximal tubular cell injury.
Ishibashi Y; Matsui T; Takeuchi M; Yamagishi S
Pharmacol Res; 2012 Mar; 65(3):297-302. PubMed ID: 22100460
[TBL] [Abstract][Full Text] [Related]
18. Linagliptin blocks renal damage in type 1 diabetic rats by suppressing advanced glycation end products-receptor axis.
Nakashima S; Matsui T; Takeuchi M; Yamagishi SI
Horm Metab Res; 2014 Sep; 46(10):717-21. PubMed ID: 24710699
[TBL] [Abstract][Full Text] [Related]
19. No Cytotoxic and Inflammatory Effects of Empagliflozin and Dapagliflozin on Primary Renal Proximal Tubular Epithelial Cells under Diabetic Conditions In Vitro.
Baer PC; Koch B; Freitag J; Schubert R; Geiger H
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31936266
[TBL] [Abstract][Full Text] [Related]
20. The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats.
Steven S; Oelze M; Hanf A; Kröller-Schön S; Kashani F; Roohani S; Welschof P; Kopp M; Gödtel-Armbrust U; Xia N; Li H; Schulz E; Lackner KJ; Wojnowski L; Bottari SP; Wenzel P; Mayoux E; Münzel T; Daiber A
Redox Biol; 2017 Oct; 13():370-385. PubMed ID: 28667906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
